AtriCure (ATRC)
(Delayed Data from NSDQ)
$22.30 USD
+0.30 (1.36%)
Updated May 10, 2024 04:00 PM ET
After-Market: $22.31 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
AtriCure (ATRC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$47.33 | $65.00 | $30.00 | 115.14% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for AtriCure comes to $47.33. The forecasts range from a low of $30.00 to a high of $65.00. The average price target represents an increase of 115.14% from the last closing price of $22.00.
Analyst Price Targets (9 )
Broker Rating
AtriCure currently has an average brokerage recommendation (ABR) of 1.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 88.89% and 11.11% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.11 | 1.11 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
2/15/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
1/2/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
11/29/2023 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.11 |
ABR (Last week) | 1.11 |
# of Recs in ABR | 9 |
Average Target Price | $47.33 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | -0.15 |